课题基金 / 基金详情

Innovative approach for high-volume production of endogenous reporter cells

Innovative approach for high-volume production of endogenous reporter cells
大批量生产内源报告细胞的创新方法
批准号:
8315758
负责人:
Robert E Finney
金额:
$22.34万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-06-05 至 2014-06-04

项目摘要

项目成果

Robert E Finney的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):基因表达报告基因测定将生物信息学数据与基因特异性生物测定相结合,以监测配体、化合物、抗体、siRNA、miRNA和肽对基因表达的影响。在细胞培养中,它们提供适用于基因调控、途径发现、靶标验证、药物发现和细胞靶标功效的台式或高通量筛选。在体内与整个动物成像一起使用,它们提供药物递送和体内靶向功效的时间和定量分析。最常用的荧光素酶基因测定法是在克隆的启动子和转录调控元件的下游放置一个易于监测的报告基因,如荧光蛋白或荧光素酶。在外源报告基因中,将载体引入受体细胞中,其中表达瞬时进行,或在“随机”和稳定整合到基因组中之后进行。外源性转录因子基因检测是高度不可预测的,并且通常不能将基因表达索引到已知的调节剂。它们可能提供错误的数据,误导研究调查,从而耗费时间和费用,使发现和发展机会无法实现。相反,在内源性报告基因中,报告基因被引入其正常染色体基因座,其中天然启动子、调控元件、局部染色体修饰和微小RNA调控序列被用于可靠和准确地指示基因调控。然而,很少有内源性人基因表达报告细胞测定是可用的,并且灵敏度限制了许多基因的准确监测。更复杂的是,目前用于生产测定的基因捕获和基因靶向方法需要在资源、时间和成本方面的大量投资,使得它们对于大多数实验室来说是无法实现的。在I期研究中,我们建议将联合收割机Xactagen先前在报告细胞敏感性方面的研究进展与创新方法相结合,以大规模生产、储存和检索内源性人类基因表达报告细胞。我们的假设是,我们将有广泛的基因覆盖范围,灵敏度,以监测表达,甚至表达不良的基因,可靠的反应,已知的基因调控,并能够检索特定的报告细胞从我们的图书馆交付给研究人员在4-6周内订购。我们的具体目标是: (1)生成19,200个阵列化基因捕获报告细胞(NIH-H292人粘液表皮样癌细胞系)的中试文库,(2)鉴定载体插入位点,并表征基因/转录单位表示,以及(3)扩增10个内源性报告细胞并验证功能。这项创新的研究提供了具有成本效益和高度加速的生产人类内源性基因表达报告细胞库在数周内,而不是数年。因此,更多的研究人员将有机会获得内源性人类报告细胞,并将能够专注于细胞培养和体内应用,而不是生产。此外,研究人员可以避免外源报告细胞的基因表达的不可预测的索引。最终,科学家将在更短的时间内以更低的成本进行更可行的研究和医学发现。 公共卫生相关性:目前生产内源性基因表达报告细胞的方法是费力的并且成本过高.本研究的最终目标是提供具有成本效益和高度加速的人内源性报告细胞文库的生产-在数周内,而不是数年。在不同的人类细胞系和干细胞中产生的数十万个容易获得的、高度敏感的、易于使用的和负担得起的基因表达报告细胞预计将提高科学研究和药物发现的生产率。
英文摘要
DESCRIPTION (provided by applicant): Gene-expression reporter assays bridge bioinformatics data with gene-specific bioassays to monitor effects of ligands, compounds, antibodies, siRNAs, miRNAs, and peptides on gene expression. In cell culture, they provide for bench top or high throughput screening applicable to gene regulation, pathway discovery, target validation, drug discovery, and cellular target efficacy. Used in vivo with whole animal imaging, they provide for temporal and quantitative analysis of drug delivery and in vivo target efficacy. The most commonly used reporter-gene assays place an easily monitored reporter gene such as a fluorescent protein or luciferase downstream to cloned promoter and transcriptional regulatory elements. In an exogenous reporter, the vector is introduced into recipient cells where expression proceeds either transiently, or after "random" and stable integration into the genome. Exogenous reporter-gene assays are highly unpredictable, and often incapable of indexing gene expression to known regulatory agents. They can provide erroneous data and mislead research investigations, thereby costing time, expense and unrealized discovery and development opportunities. In contrast, in an endogenous reporter, reporter genes are introduced at their normal chromosomal locus where native promoters, regulatory elements, local chromosomal modifications and micro-RNA regulatory sequences are utilized to reliably and accurately index gene regulation. However, very few endogenous human gene- expression reporter cell assays are available and sensitivity limits accurate monitoring of many genes. Compounding this, current gene trapping and gene targeting methods for producing assays require large investments in resources, time, and cost, making them unattainable for most laboratories. In phase I studies, we propose to combine Xactagen's prior research advances in reporter cell sensitivity with innovative methods to mass produce, store and retrieve endogenous, human gene expression reporter cells. Our hypothesis is that we will have extensive gene coverage, sensitivity to monitor expression of even poorly expressed genes, reliable responses to known gene regulators, and the ability to retrieve specific reporter cells from our libraries for delivery to researchers within 4-6 weeks of ordering. Our specific aims are: (1) Generate a pilot library of 19,200 arrayed gene-trapped reporter cells (NIH-H292 human mucoepidermoid carcinoma cell line), (2) Identify vector insertion sites, and characterize gene/transcription unit representation, and (3) Retrieve 10 endogenous reporter cells and verify functionality. This innovative research provides for cost-effective and highly expedited production of human endogenous gene expression reporter cell libraries in weeks as opposed to years. As a result, more researchers will have access to endogenous human reporter cells and will be able to focus on cell culture and in vivo applications, rather than on production. Additionally, researchers can avoid exogenous reporter cells with their unpredictable indexing of gene expression. Ultimately, scientists will make more viable research and medical discoveries in less time and at far less cost. PUBLIC HEALTH RELEVANCE: Current methods for production of endogenous gene expression reporter cells are laborious and cost- prohibitive. The ultimate goal of this research i to provide cost-effective and highly expedited production of human endogenous reporter cell libraries - in weeks as opposed to years. Hundreds of thousands of readily available, highly sensitive, easy to use, and affordable gene expression reporter cells produced in diverse human cell lines and stem cells are expected to increase productivity of scientific research and drug discovery.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Formulation and pharmacokinetics of subcutaneous administration of deferiprone for prevention of chronic heart failure following hemorrhagic myocardial infarction.
  • 批准号:
    10700370
  • 项目类别:
  • 资助金额:
    $39.0万
  • 财政年份:
    2023
  • 负责人:
    Robert E Finney
  • 依托单位:
Target Validation using Gene Knockouts in Somatic Cells
  • 批准号:
    6983135
  • 项目类别:
  • 资助金额:
    $46.83万
  • 财政年份:
    2002
  • 负责人:
    Robert E Finney
  • 依托单位:
Target Validation using Gene Knockouts in Somatic Cells
  • 批准号:
    6484456
  • 项目类别:
  • 资助金额:
    $10.0万
  • 财政年份:
    2002
  • 负责人:
    Robert E Finney
  • 依托单位:
Target Validation using Gene Knockouts in Somatic Cells
  • 批准号:
    6793746
  • 项目类别:
  • 资助金额:
    $39.29万
  • 财政年份:
    2002
  • 负责人:
    Robert E Finney
  • 依托单位:
海外基金